Dermatology

This SOCS News Update was filmed on-site at the 2025 AAD meeting, highlighting Nambudiri’s work and the launch of the AAD Clinical Image Collection.

These real-world findings on upadacitinib for atopic dermatitis highlight the drug’s efficacy and survival data among Australian patients.

This analysis suggests that exposures prior to, during, and following migration, along with structural factors are linked to skin health outcomes in migrant populations.

Without estrogen, the skin barrier weakens, leading to more severe and symptomatic psoriasis.

This analysis pointed to increased costs of biologics given the initiation of newer IL-17 and IL-23 inhibitors, suggesting the use of lower-cost options.

Dupilumab's approval marks the first new, targeted therapy for CSU in more than a decade and is the 7th indication for a disease with underlying type 2 inflammation.

Jennifer Soung, MD, joins The Medical Sisterhood to discuss her journey to launching LEADderm and how owning the podium has changed her career.

These findings highlight the impact of guselkumab on liver fibrosis progression among individuals living with psoriasis.

Revolutionizing Atopic Dermatitis 2025 Annual Meeting cochair Raj Chovatiya, MD, PhD, previews the upcoming meeting.

Mona Shahriari, MD, previews the upcoming Revolutionizing Atopic Dermatitis Annual Meeting being held in Nashville, TN from June 06-07.

A pair of experts discuss unmet needs and educational gaps related to atopic dermatitis.

Ustekinumab and its generic biofamailiar SYSA1902 exhibited clinical equivalence in terms of safety, efficacy, pharmacokinetics, and immunogenicity.

This network meta-analysis compares the relative effectiveness and safety of different monotherapies for patients living with alopecia areata.

Side effects of baricitinib were well within safety parameters, indicating the drug’s viability as a alopecia treatment for adults.

This systematic review highlights current research on ruxolitinib’s off-label use in dermatology, specifically for conditions such as alopecia and psoriasis.

These data on 5α-reductase inhibitors highlight impacts on patients with benign prostatic hyperplasia or androgenic alopecia.

This segment of the latest interview with Lawrence Eichenfield, MD, features a discussion about the ICONIC-LEAD study.

An audio recap of the top 5 stories in healthcare news from the week of 03/31-04/06.

In this interview, Lawrence Eichenfield, MD, speaks on his team’s recent research on icotrokinra for patients with moderate-to-severe plaque psoriasis.

This analysis demonstrates the effectiveness of methotrexate application via microinfusion in frontal fibrosing alopecia.

These subgroup analysis findings on icotrokinra indicate that the drug is safe and effective among adolescents and adults with moderate-to-severe psoriasis.

These data highlight the potential impacts of baricitinib across significant hair-bearing areas involved in alopecia areata.

This retrospective, real-world analysis highlights several notable findings on JAK inhibitor use among patients with alopecia areata.

In this interview, Chovatiya highlighted the unmet needs of patients with atopic dermatitis and the ways in which nemolizumab’s FDA approval addresses them.

Peter Lio, MD, discusses the value of hyperfocused meetings such as RAD and what sessions he is most looking forward to at RAD 2025.